SCHEMBL25320358

SCHEMBL25320358

CC1CCC(c2ccc3c(c2)CCO3)NC1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 1/20 0.43
PRKCI P41743 1/20 0.37
DYRK1A Q13627 5/20 0.36
DYRK1B Q9Y463 4/20 0.36
DYRK2 Q92630 3/20 0.36
PIK3CA P42336 1/20 0.36
DRD2 P14416 3/20 0.34
DRD3 P35462 3/20 0.34
BRD4 O60885 1/20 0.34
CREBBP Q92793 1/20 0.34
PDE5A O76074 1/20 0.34
KDM1A O60341 1/20 0.33
MAOA P21397 1/20 0.33
MAOB P27338 1/20 0.33
HDAC3 O15379 1/20 0.33
HDAC4 P56524 1/20 0.33
HDAC1 Q13547 1/20 0.33
HDAC7 Q8WUI4 1/20 0.33
HDAC2 Q92769 1/20 0.33
HDAC10 Q969S8 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25320354 1.00 L3MBTL1 (0.43) L3MBTL1PRKCIDYRK1ADYRK1BDYRK2
SCHEMBL25325872 0.89 L3MBTL1 (0.43) L3MBTL1PIK3CADRD2DRD3
SCHEMBL25325874 0.89 L3MBTL1 (0.43) L3MBTL1PIK3CADRD2DRD3
SCHEMBL24367134 0.78 TDP1 (0.43) L3MBTL1BRD4CREBBPMAOAMAOB
SCHEMBL29081509 0.77 ADRA2A (0.33) L3MBTL1
SCHEMBL31145194 0.77 ADRA2A (0.33) L3MBTL1
SCHEMBL31145184 0.76 L3MBTL1 (0.44) L3MBTL1PIK3CAHDAC11
SCHEMBL31145226 0.76 L3MBTL1 (0.44) L3MBTL1PIK3CAHDAC11
SCHEMBL24363934 0.76 L3MBTL1 (0.44) L3MBTL1PIK3CAHDAC11
SCHEMBL10282948 0.72 PRKCI (0.47) PRKCIDYRK1ADYRK1BDYRK2PIK3CA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250163048-A1 COMPOUNDS AND METHODS OF USE TANGO THERAPEUTICS, INC. 2025-05-22 US disclosed
EP-4469455-A1 COMPOUNDS AND METHODS OF USE Tango Therapeutics, Inc. (US) 2024-12-04 EP disclosed
WO-2023146990-A1 COMPOUNDS AND METHODS OF USE TANGO THERAPEUTICS, INC. (US) 2023-08-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250163048-A1 COMPOUNDS AND METHODS OF USE RB1, CYP1B1, REN L3MBTL1 4711/4885PRKCI 4183/4885DYRK1A 3578/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.